Recombinant Human EGLN2 Protein ，His

EGLN2, also known as EGLN1-like protein or HIF prolyl hydroxylase 2 (HPH-2), is a critical regulator of the hypoxia-inducible factor (HIF) signaling pathway, which plays a pivotal role in cellular responses to oxygen levels. The study of EGLN2 is driven by its involvement in various physiological and pathological processes, including cancer progression, metabolic adaptation, and ischemic responses. As a member of the EGLN family, EGLN2 hydroxylates specific proline residues on HIF, leading to its degradation under normoxic conditions. In contrast, low oxygen levels inhibit EGLN2 activity, allowing HIF to accumulate and activate target genes involved in angiogenesis, erythropoiesis, and glucose metabolism. Dysregulation of EGLN2 has been implicated in tumor development, where cancer cells exploit the hypoxic response to promote survival and growth in low-oxygen environments. The recombinant production of EGLN2 protein facilitates a deeper understanding of its enzymatic mechanisms, substrate interactions, and regulatory role within the HIF pathway, which is crucial for developing therapeutic strategies aimed at modulating this pathway in diseases like cancer or ischemia. Moreover, the ability to produce active EGLN2 recombinantly allows researchers to perform biochemical assays, drug screenings, and structural studies, further elucidating its function in cellular physiology and pathology. Overall, research on EGLN2 recombinant protein is essential for unlocking new avenues in targeted therapies that could effectively manipulate the HIF signaling axis in various disease contexts.